Bristol-Myers Squibb’s blockbuster immunotherapy Opdivo (nivolumab) has hit a hurdle, failing its primary endpoint in a Phase 3 trial investigating its efficacy in the treatment of newly diagnosed O6-methylguanine-DNA methyltransferase (MGMT)-unmethylated glioblastoma multiforme (GBM).
Data from the trial revealed that the drug, when used in combination with radiation, did not sufficiently improve overall survival (OS). However, Opdivo’s safety profile was found to be consistent with previous studies.
